The medical technology company now expects revenue of $46 million to $48 million for the year, compared with its previous forecast of $54 million to $57 million.

Third-quarter revenue rose 11% to $12.9 million, falling short of the $14 million analysts expected, according to FactSet. TriSalus reported a loss of $8.9 million, or 15 cents a share; analysts had forecast a loss of 13 cents a share. The stock has lost 57% this year.